CMR Surgical Files IPO Prospectus: Pioneering Minimally Invasive Surgery with Versius Robotic System

Inside a narrow glass vial, a surgical robot is performing surgery on a grape. It first used its robotic arm to tear open the grape skin, and then successfully sutured the torn grape epidermis. The less-than-one-millimeter-thick, extremely fragile grape skin was perfectly sutured by the surgical robot...

With the rapid advancement of technology, the emergence of surgical robots has undoubtedly brought infinite possibilities to clinical practice. Its advantages lie not only in overcoming the pain points of traditional surgery—such as poor precision, prolonged operative times, surgeon fatigue, and the lack of three-dimensional visual accuracy—but also in delivering better clinical outcomes for patients and shortening the learning curve for surgeons performing complex procedures.

Industry insiders have pointed out that surgical robots are currently one of the hottest sectors in the medical device industry. Abroad, there is a unicorn company called CMR Surgical (a UK-based medical device manufacturer), which is dedicated to creating surgical treatment solutions with minimal impact on patients. Relying on its proprietary “Versius” surgical robot, the company has secured hundreds of millions of dollars in financing within just a few years.

Why Has CMR Surgical Repeatedly Won the Favor of Investors? What Advanced Technologies Does the Versius Surgical Robot Possess? With These Questions in Mind, We Analyze This Company to Find Out.

According to the latest research report from Allied Market Research, the surgical robotics market was valued at $56.3 million in 2017 and is projected to reach $98.737 billion by 2024, with a compound annual growth rate (CAGR) of 8.5%.

CMR Surgical was founded in 2014 and is headquartered in Cambridge, UK. In 2018, it announced a name change from its original “Cambridge Medical Robotics (CMR)” to “CMR Surgical.” The rebranding also signaled CMR’s ambition to create next-generation surgical robots.

CMR Surgical stated that its next-generation universal surgical robotic system, Versius, planned for launch, will meet the complex demands of laparoscopic surgery, delivering exceptional flexibility and reach, thereby ushering in a new paradigm for the surgical experience.

Following the name change, CMR Surgical has more than doubled in size. Martin Frost, former CEO of CMR Surgical, stated, “We look forward to becoming a disruptor in the field of surgical procedures.”

In addition to capacity expansion, CMR Surgical announced in December 2019 the appointment of Per Vegard Nerseth as Chief Executive Officer. The former CEO, Martin Frost, assumed the role of Non-Executive Director of the company.

Martin Frost, who co-founded CMR Surgical with partners in 2014, has served as its Chief Executive Officer since the company’s inception. During his tenure, he spearheaded CMR Surgical’s commercialization and secured a record-breaking £195 million in Series C financing, propelling the company’s valuation to over £1 billion.

Newly appointed Per Vegard Nerseth comes from ABB, a global leader in the manufacturing of industrial robots and robotic systems. For the past nine years, he served as Senior Vice President and Managing Director of ABB Robotics. With over 25 years of experience in business expansion within the robotics technology sector, he drove strong performance growth for ABB during his tenure. (ABB Robotics is a multi-billion-dollar business unit with more than 7,000 employees across 53 countries/regions.)

Per Vegard Nerseth established the robotics division of ABB Engineering in China, growing it into the country’s largest robotics business. During his tenure, ABB Robotics achieved double-digit sales growth.

Erik Langaker, Chairman of CMR Surgical, stated: “We look forward to Per Vegard leading CMR through its exciting next phase.”

At its inception, CMR Surgical’s vision was to transform the existing surgical robotics market by making minimally invasive surgery—currently the least accessible and most affordable option—widely available, thereby serving the 6 million patients who require surgical procedures each year.

After several years of dedicated development, the portable robotic system Versius was launched in September 2018, immediately attracting widespread attention within the industry and emerging as a formidable competitor to the renowned “da Vinci” robotic surgical system.

What Are the Features and Advantages of the Versius Surgical Robot?

(Figure: Versius surgical robot)

According to CMR Surgical, Versius features flexible, compact robotic arms that mimic human arms. The surgeon simply sits at the console, operating two joysticks and controlling the 3D visualization system. Moreover, with a footprint of only 38 cm x 38 cm, Versius is highly compact and can be conveniently positioned around the operating table, allowing the surgical team to maintain unrestricted access to the patient at all times.

Using the Versius surgical robot, surgeons can perform a variety of minimally invasive procedures. Furthermore, Versius is easy to move between operating rooms and even hospitals, with convenient setup.

In May 2019, CMR Surgical announced that the first human clinical surgeries using the Versius surgical robotic system had been completed at Galaxy Care Hospital in India.

The procedure was conducted at Mangeshkar Hospital and Research Centre, comprising 30 laparoscopic cases covering mild, moderate, and severe gynecological and upper gastrointestinal (GI) indications. During the 30-day follow-up period, no Versius-related adverse events were reported by the surgeons.

CMR Surgical stated that Versius brings the benefits of minimally invasive surgery to patients, including faster recovery, reduced pain, and lower risks of infection and scarring.

A surgeon commented that Versius has transformed traditional laparoscopic treatment protocols. Its unique advantages, including flexible port placement, fully wristed instruments, 3D HD visualization, intuitive instrument control, and an ergonomic console design that reduces stress and fatigue, provide surgeons with superior options for surgical intervention.

It is expected that in 2020, Versius will be used in hospitals in Europe and launched globally.

Having secured four consecutive rounds of financing, each exceeding RMB 100 million, CMR Surgical has successfully joined the ranks of “unicorns” in the medical device industry, with a valuation surpassing $1 billion, thanks to its robust strength and potential.

The specific financing details are as follows: In June 2016, CMR Surgical secured $20 million in Series A funding; in September 2017, it raised $26 million in Series A+ funding; in June 2018, it obtained $100 million in Series B funding; and in September 2019, it completed a $243 million Series C financing round. In summary, its total funding over the four-year period amounted to $389 million.

(Financing Chart)

CMR Surgical stated that global revenue from robotic surgical equipment is approximately $4 billion annually, growing at a rate of 20% per year. Revenue is projected to reach $20 billion by 2025. The accelerated expansion aims not only to bring Versius to market but also to expand research and development, producing more surgical robots that closely align with market needs.

The CEO of CMR Surgical stated that the future market is large enough to support three or four different robotic platforms. Hospitals often wish to purchase more than one system for various purposes; he is confident that Versius will be among them, and that the company will stand “shoulder to shoulder” with Intuitive and other major groups.

Certainly, part of this confidence stems from Versius receiving the CE mark in March 2019 for use in gastrointestinal surgeries, hernia repairs, and cholecystectomies. Additionally, CMR Surgical’s pricing strategy represents a significant advantage, employing a subscription model under which customers pay an annual fee for a managed service agreement that provides access to the robotic system and unlimited single-use instruments.